Cronos Group Inc. (CRON) Earnings Call Transcript & Summary

May 8, 2025

Toronto Stock Exchange CA Health Care Pharmaceuticals earnings 17 min

Earnings Call Speaker Segments

Operator

operator
#1

Good morning, everyone. I'm Jacinda <<inaudible>>, and I'll be serving as your conference operator for today. I'd like to extend a welcome to all of you joining the Cronos Group 2025 First Quarter Earnings Conference Call. Please note that this call is being recorded. Right now, I'll hand things over to Terry Doucet, who serves as Cronos General Counsel and Corporate Secretary. Terry, please go ahead.

Terry Doucet

executive
#2

Thank you, Jacinda <<inaudible>>, and thanks for being with us today as we go through Cronos' financial and business performance for the first quarter of 2025. With me today are Mike Gorenstein, our Chairman, President and CEO, and Anna Shlimak, our CFO. This morning Cronos put out a news release announcing our financial results, and it's filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will also be posted on our website under Investor Relations. Before I hand the call over to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Those forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from what those forward-looking statements project. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings, which are available on our website, and by which any forward-looking statements made during this call are qualified in their entirety. You can also find information about non-GAAP financial measures, including reconciliations to U.S. GAAP, in the earnings materials available on our website. Finally, throughout this conference call we will be making statements regarding market share information; and unless otherwise stated, all market share data is provided by Hifyre.

Terry Doucet

executive
#3

We're going to give our prepared remarks now, and after that we'll open things up for a question-and-answer session. So with that, I'll hand things over to Mike Gorenstein, Cronos' Chairman, President and CEO.

Mike Gorenstein

executive
#4

Thanks, Terry, and good morning, everyone. The targets we've set for 2025 are the same ones we've had all along — the strategic objectives that have consistently steered Cronos. We're still concentrated on being the leader in product innovation and quality, along with distribution, and on taking those strengths and turning them into top positions in cannabis markets around the world. Looking forward, we anticipate the chance to keep up robust revenue expansion, and over time we intend to produce further margin gains by means of operating leverage and ongoing cost discipline. Now, on to brand news. At quarter's end, our Spinach brand stood as the number two brand in Canada, holding 4.6% market share, which shows category-leading results across a range of formats. Within the flower category, Spinach fell to the number 3 position, with market share of 5.1%. Robust and rising consumer appetite for our flower products has created supply constraints that have held back growth for that Spinach brand, though we view this slower growth as temporary. Such shortages are a reflection of how exceptionally popular our flower offerings are. And although this pent-up demand poses a near term challenge, we're taking deliberate steps to make sure we address it quickly. Our team is carefully distributing current inventory so that our most sought after products stay available across markets.

Mike Gorenstein

executive
#5

When our GrowCo expansion is finished, that will be a pivotal moment for us, opening up meaningful extra capacity during the second half of 2025, and that capacity will let us take advantage of this demand. We stay firmly committed to delivering the cannabis industry’s best flower products, and our strategic investment in GrowCo puts us in position to strengthen our market share as supply becomes available. Our lead in edibles is still strong, and there we hold the number one position with 20.7% market share. The SOURZ by Spinach line keeps setting the standard, capturing over 23% of the gummy category. We have reinforced that lead with new innovative offerings, Fully Blasted gummies featuring 10 milligram THC and rare cannabinoids, including 3 new standout flavors: mango lime with CBC, peach passionfruit CBN and CBD, and strawberry watermelon with CBG. In the vape category, we have achieved the number 4 position overall with 5.7% share, while our vape cartridges specifically rank even higher at number 3 with 7% share. We successfully extended our winning SOURZ flavor profiles into the vape category with 3 new rare cannabinoid infused offerings: mango kiwi haze with CBC, peach passionfruit crush with CBN, and strawberry watermelon with CBG. Our premium Lord Jones brand continues to demonstrate the category specific strengths across the Canadian market.

Mike Gorenstein

executive
#6

The brand still holds the number 3 spot among chocolate brands, with 9.6% market share, reinforcing its standing as a leader in confectionery, and in January it broadened its lineup by launching a fudge brownie bite that has a THC, CBN and CBD ratio. In the hash-infused pre-roll segment, the Lord Jones brand leads the category with an impressive 30.1% market share. That number 1 ranking shows how we can make differentiated, high quality products that connect with discerning cannabis consumers. Results across several categories show Lord Jones can secure premium positioning while also delivering strong performance in specialized market segments. Turning to the international side of the business, the Peace Naturals brand and product portfolio keep growing. We overhauled the Peace Naturals portfolio in Israel with a revised pricing strategy and focused cultivars that address the needs of our patient base. According to pharmacy data collected by Cronos, Peace Naturals finished the quarter as the number 1 flower brand in Israel with well over 20% market share. Q1 launches included two new Peace Naturals strain specific cannabis oils, made to deliver the full benefits and essence of each strain. Since 2017 we have been investing in building our team and business in Israel, and by consistently delivering high quality products that draw on our extensive investments in genetics, breeding, cultivation, and R&D, we have earned the trust of Israeli patients and pharmacies and achieved the leading share position in the market.

Mike Gorenstein

executive
#7

Cronos Israel's team delivered an outstanding Q1, with revenue for the business up more than 40% compared with a year earlier and meaningful share gains in a market that is still very competitive and dynamic. From a sales volume, revenue and margin standpoint, Q1 stood as a record for Cronos Israel, and during the period Israel sales accounted for almost 30% of our consolidated net revenue. After looking into anti-dumping allegations — which Cronos firmly disputes and strongly believes have no basis — on April 10 Israel's ministry, the Minister of Economy and Industry, announced that Israel would place tariffs of upto 165% on Canadian cannabis, and that would include imports from Cronos. The Ministry of Health and the Competition Authority both opposed the proposed tariffs, and on April 25 Israel's Minister of Finance vetoed them. Notwithstanding that veto, on April 29 the Minister of Economy and Industry said publicly that he would push ahead and seek final approval for the tariff. This has no precedent and runs counter to the law, and it threatens to hit patients and IDF veterans hard by driving up prices, narrowing the choices available to patients and lowering quality. We remain dedicated to Israel, where we have invested and operated for almost a decade, constructing a strong supply chain in a competitive medical market.

Mike Gorenstein

executive
#8

As Israel's leading medical provider, we had a record quarter across the entire P&L <<inaudible>>, and that stands in stark contrast to the claims that we are dumping. At Cronos, we believe the market structure should be fair and equitable for Israel's medical cannabis patients, and we'll keep advocating on their behalf by opposing these tariffs, because patients are counting on us and on our products. Our international expansion keeps gaining traction in key markets. In Germany, we expect additional growth as our GrowCo capacity expansion comes online, and we keep building demand and momentum in The UK market. As we look toward the rest of 2025, our focus is on successfully bringing the GrowCo expansion online to address current supply constraints, continuing to realize operational efficiencies and operating leverage, pursuing international expansion in markets offering the strongest ROI, and maintaining our disciplined approach to cost management. Cronos maintains the strongest balance sheet in the industry, with no debt and cash equivalents and short-term investments of $838 million, which reinforces our ability to invest in growth, innovation and global expansion. And today, we announced that our Board has authorized a $50 million share repurchase program. Now, I'll turn it over to Anna to walk you through the first quarter financials.

Anna Shlimak

executive
#9

Thanks, Mike, and good morning to everyone. I'll walk you through the results for the first quarter of 2025, which now reflect GrowCo's financials being consolidated. Consolidated net revenue came in at $32.3 million, up 28% versus the same period last year, and constant currency net revenue growth was even stronger at 33% year-over-year. For Cronos on a standalone basis, excluding GrowCo, net revenue was $29.4 million, which works out to 16% year-over-year growth, or 21% on a constant currency basis. GrowCo contributed $2.9 million of net revenue in Q1 2025. All told, the rise in consolidated net revenue came from greater flower sales in Israel, increased flower sales internationally, and stronger extract sales in Canada. Gross profit for the first quarter reached $13.7 million, equal to a 43% gross margin. If we adjust for the inventory step up tied to the GrowCo transaction that flowed into cost of sales, adjusted gross profit was $14.3 million, equal to a 44% adjusted gross margin. In Q1 2025, we sold through the remaining inventory that had been stepped up to fair market value under the purchase accounting adjustment, so gross profit in upcoming quarters won't be affected by that adjustment. The 44% adjusted gross margin in Q1 2025 marks a substantial improvement over 18% in Q1 2024.

Anna Shlimak

executive
#10

Regional mix shift, reduced direct costs, and production efficiencies are what drive this improvement, along with timing benefits that flattered Q1 2025 gross margin. In light of those timing benefits, we'd see the blended adjusted gross margin across Q4 2024 and Q1 2025 as a better indication of where underlying margins for the business currently stand. Operating expenses excluding restructuring costs and impairment charges came to $17.3 million in the quarter, down nearly $1 million year over year, mainly on lower sales and marketing costs. A reversal of previously accrued bonuses helped reported operating expenses in the quarter, and part of the OpEx reduction was timing related, reflecting the cadence of sales and marketing activations and R&D activities. Consequently, for the balance of 2025 we expect quarterly operating expenses to run above Q1 2025 levels, though they should stay relatively flat year over year. Adjusted EBITDA for the first quarter was $2.3 million, a $13 million improvement from the prior year period. Increased revenue, significantly higher adjusted gross margins, and reductions in operating expenses drove that improvement. While part of the gross margin improvement in the quarter stemmed from underlying business improvements, another part was timing related.

Anna Shlimak

executive
#11

Part of the drop in operating expenses comes from the efficiency steps we keep taking, and part of it reflects benefits from how expenses were timed along with the reversal of bonus accruals. Now moving to the balance sheet and the cash flow statement. At quarter's end, cash and cash equivalents plus short term investments totaled $838 million, which is $21 million lower than Q4 2024, mainly because of a net working capital outflow of roughly $50 million and about $50 million in CapEx spending; these were partly offset by positive cash flow from operations before working capital changes of approximately $12 million. Most of that CapEx ties to the facility expansion at GrowCo that we announced earlier. CapEx spending will stay elevated over the next couple of quarters while the GrowCo expansion proceeds and wraps up, and after that we expect CapEx levels to come down to a more normal level. To sum up, we delivered a strong quarter, and with the large scale capacity expansion at GrowCo, we are well positioned for continued medium and long-term improvement in our operating fundamentals, even with shorter term headwinds from supply constraints and from gross margin and OpEx normalization over the next couple of quarters. With that, I would like to hand it back to Mike for a brief comment before going into Q&A.

Mike Gorenstein

executive
#12

Thank you, Anna. Looking forward, we stay intensely concentrated on three strategic pillars: breakthrough innovation, operational excellence, and disciplined expansion around the globe. Our core business is doing well, holding market and category leadership positions that show how strong our brands and execution are, and our team has generated remarkable momentum as we head into 2025. As we progress through this year, several catalysts have us especially excited: our forthcoming capacity expansion, new product launches, and growth in international markets. Thanks to our best-in-class balance sheet and market-leading products, we have what we need to navigate and succeed in the fast-changing global cannabis industry. With that, I'll open the line for questions.

Operator

operator
#13

It looks like we have no questions right now. Thanks for joining today’s conference. Oh! A participant has just joined the queue. Bill Kirk at ROTH, your line is open.

Bill Kirk

analyst
#14

Mike, you mentioned product shortages somewhat, and that's not something we've really had to consider much in the years since adult use became legal in Canada. So I suppose what I'm asking is whether the shortage is tied more specifically to Cronos products and demand, or whether it's also a wider phenomenon across the industry at the moment?

Anna Shlimak

executive
#15

Hey Bill, my apologies. I believe Mike got disconnected by mistake. With any luck, he’ll rejoin shortly. But really, it comes down to having the right product available for the market. And I think what you’re seeing is a scarcity of quality product out there. That’s an issue we’re addressing, and it’s among the main motivations behind putting money into the GrowCo expansion. And with the top-tier genetics and top-tier products we’ve got in Canada and Israel, we want to make more of them available around the world.

Bill Kirk

analyst
#16

Okay. And then Anna, I believe you mentioned that the underlying gross margin will probably be a mix of what we saw in 1Q and 4Q. Once the GrowCo expansion is finished, how might underlying gross margin shift?

Anna Shlimak

executive
#17

That's right. So the blended rate we saw between Q4 and Q1 is what we expect for the remainder of the year. I think, all else being equal, the Cronos GrowCo expansion should be neutral to accretive to gross margins, because with the larger cultivation area, we'll be able to leverage the facility's fixed costs incrementally better. But ramping up and hitting our stride there will also take us time.

Bill Kirk

analyst
#18

All right, that's great. Thanks a lot.

Operator

operator
#19

Thanks. That brings the Q&A portion to a close. We appreciate everyone joining us on today's call. That wraps up the program. You're free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.